{"id":"NCT02634801","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment","officialTitle":"A 24-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients With Moderate-to-Severe Plaque Psoriasis Who Are Naive to Systemic Treatment With an Extension Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-20","primaryCompletion":"2016-11-29","completion":"2017-11-14","firstPosted":"2015-12-18","resultsPosted":"2018-07-18","lastUpdate":"2019-10-09"},"enrollment":162,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Fumaric Acid Esters","otherNames":[]},{"type":"DRUG","name":"Methotrexate","otherNames":[]},{"type":"DRUG","name":"Ixekizumab","otherNames":["LY2439821"]}],"arms":[{"label":"Ixekizumab","type":"EXPERIMENTAL"},{"label":"Fumaric Acid Esters","type":"ACTIVE_COMPARATOR"},{"label":"Methotrexate","type":"ACTIVE_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the efficacy of ixekizumab compared to fumaric acid esters (FAE) and methotrexate (MTX) in participants with moderate-to-severe plaque psoriasis who are naive to systemic treatment.","primaryOutcome":{"measure":"Percentage of Participants With a â‰¥75% Improvement in Psoriasis Area and Severity Index (PASI 75) at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Ixekizumab","deltaMin":90.7,"sd":null},{"arm":"Fumaric Acid Esters","deltaMin":22.2,"sd":null},{"arm":"Methotrexate","deltaMin":70.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"},{"comp":"OG000 vs OG002","p":"0.0137"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":21,"countries":["Germany"]},"refs":{"pmids":["31376153"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":54},"commonTop":["Nasopharyngitis","Diarrhoea","Abdominal pain upper","Headache","Injection site reaction"]}}